🇺🇸 FDA
Patent

US 12098144

Piperazine indazole glucocorticoid receptor antagonists

granted A61PA61P43/00

Quick answer

US patent 12098144 (Piperazine indazole glucocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61P, A61P43/00